KR102177899B1 - 니트록실 공여체를 포함하는 약제학적 조성물 - Google Patents

니트록실 공여체를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR102177899B1
KR102177899B1 KR1020157022200A KR20157022200A KR102177899B1 KR 102177899 B1 KR102177899 B1 KR 102177899B1 KR 1020157022200 A KR1020157022200 A KR 1020157022200A KR 20157022200 A KR20157022200 A KR 20157022200A KR 102177899 B1 KR102177899 B1 KR 102177899B1
Authority
KR
South Korea
Prior art keywords
cyclodextrin
formula
compound
pharmaceutical composition
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157022200A
Other languages
English (en)
Korean (ko)
Other versions
KR20150108879A (ko
Inventor
빈센트 제이콥 칼리쉬
존 리어든
프레더릭 아서 브룩필드
스티븐 마틴 코트니
리사 마리 프로스트
존 피. 토스카노
Original Assignee
카르디옥실 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카르디옥실 파마슈티칼스 인코포레이티드 filed Critical 카르디옥실 파마슈티칼스 인코포레이티드
Publication of KR20150108879A publication Critical patent/KR20150108879A/ko
Application granted granted Critical
Publication of KR102177899B1 publication Critical patent/KR102177899B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157022200A 2013-01-18 2014-01-17 니트록실 공여체를 포함하는 약제학적 조성물 Expired - Fee Related KR102177899B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US61/754,237 2013-01-18
US201361782781P 2013-03-14 2013-03-14
US61/782,781 2013-03-14
PCT/US2014/012089 WO2014113700A1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Publications (2)

Publication Number Publication Date
KR20150108879A KR20150108879A (ko) 2015-09-30
KR102177899B1 true KR102177899B1 (ko) 2020-11-12

Family

ID=50064795

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157022200A Expired - Fee Related KR102177899B1 (ko) 2013-01-18 2014-01-17 니트록실 공여체를 포함하는 약제학적 조성물
KR1020157022192A Active KR102277165B1 (ko) 2013-01-18 2014-01-17 향상된 치료 지수를 갖는 니트록실 공여체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157022192A Active KR102277165B1 (ko) 2013-01-18 2014-01-17 향상된 치료 지수를 갖는 니트록실 공여체

Country Status (29)

Country Link
US (13) US10245249B2 (cg-RX-API-DMAC7.html)
EP (5) EP2945621B1 (cg-RX-API-DMAC7.html)
JP (5) JP6533159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102177899B1 (cg-RX-API-DMAC7.html)
CN (4) CN110179777B (cg-RX-API-DMAC7.html)
AU (5) AU2014207408C1 (cg-RX-API-DMAC7.html)
BR (2) BR112015017241B1 (cg-RX-API-DMAC7.html)
CA (2) CA2898443C (cg-RX-API-DMAC7.html)
CY (3) CY1120535T1 (cg-RX-API-DMAC7.html)
DK (3) DK2945621T3 (cg-RX-API-DMAC7.html)
ES (4) ES2882279T3 (cg-RX-API-DMAC7.html)
HK (1) HK1251170B (cg-RX-API-DMAC7.html)
HR (3) HRP20180121T1 (cg-RX-API-DMAC7.html)
HU (3) HUE046722T2 (cg-RX-API-DMAC7.html)
IL (4) IL239906B (cg-RX-API-DMAC7.html)
LT (3) LT2945620T (cg-RX-API-DMAC7.html)
MX (2) MX363843B (cg-RX-API-DMAC7.html)
NZ (4) NZ748769A (cg-RX-API-DMAC7.html)
PL (3) PL2945620T3 (cg-RX-API-DMAC7.html)
PT (3) PT3284463T (cg-RX-API-DMAC7.html)
RS (3) RS59434B1 (cg-RX-API-DMAC7.html)
RU (3) RU2684916C2 (cg-RX-API-DMAC7.html)
SG (6) SG10201913286PA (cg-RX-API-DMAC7.html)
SI (3) SI3284463T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201900575T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802211T4 (cg-RX-API-DMAC7.html)
TW (3) TWI619491B (cg-RX-API-DMAC7.html)
WO (2) WO2014113696A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201505090B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007227457B2 (en) 2006-03-17 2013-03-28 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
MX363843B (es) 2013-01-18 2019-04-05 Cardioxyl Pharmaceuticals Inc Composiciones farmaceuticas que comprenden donadores de nitroxilo.
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
CN110520116A (zh) 2017-01-03 2019-11-29 卡尔迪奥克斯尔制药公司 供硝酰化合物的给予方法
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) * 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2009042970A1 (en) 2007-09-26 2009-04-02 Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
BR9506549A (pt) * 1994-01-19 1997-10-14 Byk Nederland Bv Derivados de benzilamina contendo grupos nitróxi e sua aplicação para o tratamento de enfermidades cardiovasculares bem como de pressão interna dos olhos elevada
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
CA2306914A1 (en) 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Antirheumatic
DK0930302T3 (da) * 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
WO1999063385A1 (en) 1998-06-04 1999-12-09 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
DK1341779T3 (da) 2000-12-13 2006-10-30 Wyeth Corp Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2007522135A (ja) 2004-01-30 2007-08-09 ザ ジョンズ ホプキンス ユニバーシティ ニトロキシル前駆化合物および使用方法
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
DK2278975T3 (en) 2008-05-07 2016-12-19 Cardioxyl Pharmaceuticals Inc NOVEL nitroso compounds WHICH NITROXYLDONORER AND METHODS OF USE THEREOF
IN2012DN05028A (cg-RX-API-DMAC7.html) 2009-12-07 2015-10-23 Univ Johns Hopkins
CA2782110A1 (en) * 2009-12-07 2011-06-16 Johns Hopkins University N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives
CN108409662B (zh) 2011-10-17 2021-10-26 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
MX363843B (es) 2013-01-18 2019-04-05 Cardioxyl Pharmaceuticals Inc Composiciones farmaceuticas que comprenden donadores de nitroxilo.
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2009042970A1 (en) 2007-09-26 2009-04-02 Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension

Also Published As

Publication number Publication date
IL259233A (en) 2018-07-31
IL239952B (en) 2018-05-31
CA2898445A1 (en) 2014-07-24
HRP20191919T8 (hr) 2021-10-01
ES2705240T3 (es) 2019-03-22
MX2015009276A (es) 2015-10-30
BR112015017241A8 (pt) 2019-10-29
US9586896B2 (en) 2017-03-07
EP2945620A1 (en) 2015-11-25
RU2684916C2 (ru) 2019-04-16
HK1216857A1 (en) 2016-12-09
DK3284463T3 (da) 2019-10-28
DK2945620T3 (en) 2018-02-05
SG10201802862WA (en) 2018-05-30
US20240066002A1 (en) 2024-02-29
ES2751922T3 (es) 2020-04-02
AU2018241168B2 (en) 2020-04-02
BR112015017251A2 (pt) 2017-07-11
RU2676277C2 (ru) 2018-12-27
TWI619491B (zh) 2018-04-01
TWI686193B (zh) 2020-03-01
LT2945620T (lt) 2018-02-12
JP6656345B2 (ja) 2020-03-04
JP6533159B2 (ja) 2019-06-19
PT3284463T (pt) 2019-10-30
US20150175566A1 (en) 2015-06-25
PT2945621T (pt) 2019-01-21
AU2018241168A1 (en) 2018-11-01
LT3284463T (lt) 2019-11-11
SI3284463T1 (sl) 2019-12-31
JP6801045B2 (ja) 2020-12-16
HK1216858A1 (en) 2016-12-09
SMT201900575T1 (it) 2019-11-13
AU2014207408C1 (en) 2018-09-06
HRP20191919T1 (hr) 2020-01-10
EP3284463B1 (en) 2019-07-24
IL259233B (en) 2019-10-31
JP6449171B2 (ja) 2019-01-09
US9968584B2 (en) 2018-05-15
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
EP3427728A1 (en) 2019-01-16
SI2945620T1 (en) 2018-01-31
US10245249B2 (en) 2019-04-02
EP3284463A1 (en) 2018-02-21
US20200163929A1 (en) 2020-05-28
HUE041861T2 (hu) 2019-06-28
MX373176B (es) 2020-04-22
AU2014207408A1 (en) 2015-08-13
EP2945620B1 (en) 2017-11-22
CA2898445C (en) 2022-05-03
AU2014207404B2 (en) 2017-10-19
TR201802211T4 (tr) 2018-03-21
ES2659969T3 (es) 2018-03-20
CN105142627B (zh) 2019-06-21
US20170151210A1 (en) 2017-06-01
BR112015017241A2 (pt) 2017-07-11
BR112015017241B1 (pt) 2021-10-26
CY1122177T1 (el) 2020-11-25
KR20150108879A (ko) 2015-09-30
US10548872B2 (en) 2020-02-04
SI2945621T1 (sl) 2019-01-31
IL239906B (en) 2018-05-31
JP2016505044A (ja) 2016-02-18
TWI712409B (zh) 2020-12-11
MX363843B (es) 2019-04-05
AU2014207408A8 (en) 2015-08-27
US11304924B2 (en) 2022-04-19
IL258882A (en) 2018-06-28
RU2015134583A (ru) 2017-02-22
PL2945620T3 (pl) 2018-03-30
SG10201802855TA (en) 2018-05-30
HUE036589T2 (hu) 2018-07-30
US9156804B2 (en) 2015-10-13
SG10201913441RA (en) 2020-03-30
JP2019172682A (ja) 2019-10-10
US10213408B2 (en) 2019-02-26
CN110179777B (zh) 2022-07-15
EP3567031A1 (en) 2019-11-13
CA2898443C (en) 2022-05-31
US20180235927A1 (en) 2018-08-23
TW201934120A (zh) 2019-09-01
US12186301B2 (en) 2025-01-07
HK1251170B (en) 2020-04-09
IL239906A0 (en) 2015-08-31
US11273143B2 (en) 2022-03-15
EP3427728B1 (en) 2021-07-07
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
ES2882279T3 (es) 2021-12-01
WO2014113700A1 (en) 2014-07-24
LT2945621T (lt) 2019-01-10
AU2014207404A1 (en) 2015-08-13
NZ709985A (en) 2020-05-29
US11786501B2 (en) 2023-10-17
KR102277165B1 (ko) 2021-07-14
TW201442702A (zh) 2014-11-16
CA2898443A1 (en) 2014-07-24
TW201446242A (zh) 2014-12-16
JP6311038B2 (ja) 2018-04-11
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
NZ748769A (en) 2020-05-29
WO2014113696A1 (en) 2014-07-24
US20140206769A1 (en) 2014-07-24
CN110179777A (zh) 2019-08-30
CN105142627A (zh) 2015-12-09
ZA201604798B (en) 2018-01-31
BR112015017251A8 (pt) 2019-10-29
PT2945620T (pt) 2018-02-21
RS59434B1 (sr) 2019-11-29
US20220193026A1 (en) 2022-06-23
SMT201800088T1 (it) 2018-03-08
CY1121480T1 (el) 2020-05-29
US20190133990A1 (en) 2019-05-09
AU2018203240A1 (en) 2018-05-31
CN108610312A (zh) 2018-10-02
MX2015009269A (es) 2015-10-30
CN105073105B (zh) 2018-02-27
PL3284463T3 (pl) 2019-12-31
ZA201505090B (en) 2016-10-26
AU2018203240B2 (en) 2019-12-12
US10517847B2 (en) 2019-12-31
WO2014113700A9 (en) 2014-10-09
JP2016510326A (ja) 2016-04-07
HRP20182144T1 (hr) 2019-03-08
JP2017125015A (ja) 2017-07-20
CN105073105A (zh) 2015-11-18
IL239952A0 (en) 2015-08-31
JP2019089764A (ja) 2019-06-13
US20210015784A1 (en) 2021-01-21
SG11201505567RA (en) 2015-09-29
BR112015017251B1 (pt) 2021-10-26
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
RU2015134581A (ru) 2017-02-27
US10792273B2 (en) 2020-10-06
NZ709986A (en) 2020-01-31
US20190224159A1 (en) 2019-07-25
HRP20180121T1 (hr) 2018-02-23
KR20150107853A (ko) 2015-09-23
RU2018143994A (ru) 2019-01-16
DK2945621T3 (en) 2019-02-11
RS58174B1 (sr) 2019-03-29
HUE046722T2 (hu) 2020-03-30
SG10201913286PA (en) 2020-02-27
AU2017200147B2 (en) 2018-07-05
SMT201900027T1 (it) 2019-02-28
US8987326B2 (en) 2015-03-24
AU2014207408B2 (en) 2018-03-01
NZ748771A (en) 2019-12-20
PL2945621T3 (pl) 2019-05-31

Similar Documents

Publication Publication Date Title
AU2018203240B2 (en) Pharmaceutical compositions comprising nitroxyl donors
HK40001419B (en) Pharmaceutical compositions comprising nitroxyl donors
HK40001419A (en) Pharmaceutical compositions comprising nitroxyl donors
HK1216858B (en) Pharmaceutical compositions comprising nitroxyl donors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20231107

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231107